Olanib 150 (Olaparib) 150 mg Tablets

Indicated for the treatment of adult patients with:

• 🔹 Ovarian Cancer: Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• 🔹 Breast Cancer: Germline BRCA-mutated, HER2-negative metastatic breast cancer.
• 🔹 Pancreatic Cancer: Maintenance treatment for metastatic pancreatic cancer (gBRCA mutated).
• 🔹 Prostate Cancer: Metastatic castration-resistant prostate cancer with HRR gene mutations.

Packaging: 150 mg film-coated tablets.

⚠️ ADMINISTRATION PROTOCOL (Tablets):

• Recommended Dose: 300 mg taken twice daily.
• Per Dose: Take 2 tablets (150 mg each) in the morning and 2 in the evening.
• Total Daily Dose: 600 mg.
• Food Intake: Can be taken with or without food.
• Administration: Swallow tablets whole. Do not chew, crush, or split.

• Hypersensitivity to Olaparib.
• Pregnancy and breastfeeding (embryo-fetal toxicity).
• Severe renal or hepatic impairment.

Common adverse reactions include:

• 🩸 Blood: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood tests are required.
• 📉 Digestive: Nausea, vomiting, fatigue, diarrhea, dysgeusia (taste changes).
• 🌀 Respiratory: Dyspnea (shortness of breath), cough.
• Patients should monitor for signs of fatigue and weakness.